Does optimal ADMA support preserved nitric oxide signaling?

ADMA (asymmetric dimethylarginine) is an endogenous regulator of endothelial nitric-oxide signaling. The overall claim is biologically well grounded, although “optimal ADMA” is not an established clinical target or threshold.

Mechanistic evidence

• ADMA directly and competitively inhibits endothelial nitric-oxide synthase (eNOS) at the L-arginine binding site. Purified/recombinant eNOS studies show increased apparent Km with little change in Vmax, consistent with competitive inhibition; reported Ki values are approximately 0.9–4.8 µM.
• Because eNOS converts L-arginine to nitric oxide (NO) and L-citrulline, ADMA-mediated eNOS inhibition can reduce endothelial NO production. Endothelial-cell studies demonstrate concentration-dependent suppression of eNOS-derived NO, with clearer effects at extracellular ADMA around 5–10 µM or higher.
• Physiological relevance depends on context. Healthy circulating ADMA is generally 0.3–1.0 µM, and estimated inhibition at plasma concentrations near 0.4–0.5 µM may be under 5%; however, endothelial intracellular ADMA may be 5–20-fold higher than plasma, and the L-arginine:ADMA ratio materially influences inhibition.

Human vascular and cardiovascular evidence

• In 2,096 healthy adults aged 24–39 years, higher ADMA was independently associated with lower brachial flow-mediated dilation—a measure of NO-dependent endothelial vasodilation—after adjustment for cardiovascular risk factors and kidney function (β −1.56 ± 0.62 percentage points; P=0.01).
• A meta-analysis of 22 prospective cohorts found that individuals in the highest versus lowest ADMA tertile had greater cardiovascular-disease risk (RR 1.42, 95% CI 1.29–1.56).

Clinical interpretation

• Bottom line: Avoiding pathophysiologically elevated ADMA plausibly supports preserved NO signaling and endothelial function. However, no validated “optimal” ADMA concentration, routine testing indication, or proven outcome benefit from ADMA-directed lowering currently exists; ADMA is best viewed as a mechanistically informative, investigational biomarker rather than a stand-alone treatment target.